A multicenter randomized controlled trial and metabolomics exploration of Traditional Chinese Medicine pattern-based therapy for stable chronic obstructive pulmonary disease

doi:10.19852/j.cnki.jtcm.20260206.001

Journal of Traditional Chinese Medicine ›› 2026, Vol. 46 ›› Issue (3): 652-665.DOI: 10.19852/j.cnki.jtcm.20260206.001

• Original Articles • Previous Articles Next Articles

A multicenter randomized controlled trial and metabolomics exploration of Traditional Chinese Medicine pattern-based therapy for stable chronic obstructive pulmonary disease

DING Huanzhang¹^,², WANG Hui³^,⁴, YANG Qinjun³^,⁴, MA Xiao³^,⁴, WU Di¹^,⁴, LI Qiao⁵, ZHENG Caixia⁶, LU Jiasheng⁷, WU Chengming⁸, HUANG Pingfu⁹, CHEN Zhixiang¹⁰, WANG Shihan¹¹, FENG Jihong¹², LIU Jian¹², SUN Dengdi¹³, ZHU Jie³^,⁴, TONG Jiabing¹^,⁴, GAO Yating¹^,⁴, LI Zegeng¹^,⁴()

¹ Department of Respiratory Medicine, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230000, China
² Fuyang Medical School, Fuyang Normal University, Fuyang 236037, China
³ College of Traditional Chinese Medicine, Anhui University of Chinese Medicine, Hefei 230000, China
⁴ Anhui Provincial Key Laboratory for the Application and Transformation of Traditional Chinese Medicine in the Prevention and Treatment of Major Respiratory Diseases, Hefei 230000, China
⁵ Department of Respiratory Medicine, Jieshou Hospital of Traditional Chinese Medicine, Jieshou 236500, China
⁶ Department of Respiratory Medicine, Huaibei Hospital of Traditional Chinese Medicine, Huaibei 235000, China
⁷ Department of Respiratory Medicine, Taihe Hospital of Traditional Chinese Medicine, Taihe 236600, China
⁸ Department of Respiratory Medicine, Bozhou Hospital of Traditional Chinese Medicine, Bozhou 236000, China
⁹ Department of Respiratory Medicine, Chuzhou Integrated Traditional Chinese and Western Medicine Hospital, Chuzhou 239000, China
¹⁰ Department of Respiratory Medicine, Wuhu Hospital of Traditional Chinese Medicine, Wuhu 241000, China
¹¹ Department of Respiratory Medicine, Lu'an Hospital of Traditional Chinese Medicine, Lu'an 237000, China
¹² Department of Respiratory Medicine, Second Affiliated Hospital of Tianjin University of Chinese Medicine, Tianjin 300250, China
¹³ School of Computer Science and Technology, Anhui University, Hefei 230601, China

Received:2025-04-14 Accepted:2025-08-11 Online:2026-06-15 Published:2026-02-06
Contact: Prof. LI Zegeng, Department of Respiratory Medicine, the First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230000, China; Anhui Provincial Key Laboratory for the Application and Transformation of Traditional Chinese Medicine in the Prevention and Treatment of Major Respiratory Diseases, Hefei 230000, China. ahzyfb@sina.com, Telephone: +86-13805516609
About author:First author contact:
DING Huanzhang and WANG Hui are co-first authors and contributed equally to this work
Supported by:
National Natural Science Foundation of China-funded Project: Discussion of Molecular Mechanisms of Xin'an Guben Peiyuan Method Based on Inflammation Immune Network Regulation to Improve Chronic Obstructive Pulmonary Disease Patient Perception Through Formula Syndrome Correspondence(U20A20398);Natural Science Foundation of Anhui Province-funded Project: Experimental Study on Regulation of Immune Function in Chronic Obstructive Pulmonary Disease Rats with Phlegm Stasis Obstructing Lung Syndrome by Yiqi Huatan Quyu Formula Through Lung Gut Microbiota Imbalance(2208085QH264)

1. .pdf(1130KB)

Abstract

Abstract:

OBJECTIVE: To evaluate the efficacy of Traditional Chinese Medicine (TCM) pattern-based comprehensive therapy on stable chronic obstructive pulmonary disease (COPD) patients and its influence on metabolic profiles.

METHODS: In this multicenter trial, 270 participants from nine hospitals were randomly divided into a trial group and a control group at a 1∶2 ratio. The trial group received Tiotropium Bromide Powder for Inhalation (TBPI) plus one of three TCM granules [Shenqi Wenfei formula (参芪温肺方), Shenqi Buzhong formula (参芪补中方), or Shenqi Tiaoshen formula (参芪调肾方)], while the control group got only TBPI. The study had a 24-week treatment and 52-week follow-up. The main outcome was the frequency of acute COPD exacerbations. Secondary outcomes included related rates, scores on COPD assessment test (CAT) and modified medical research council (mMRC) dyspnea scale, 6-min walk test (6MWT) distance, and lung function, measured at weeks 0, 24, and 52. Serum samples for metabolomics were taken from the trial group before/after treatment and from healthy people.

RESULTS: A total of 256 out of 270 patients completed the study. The trial group had fewer acute exacerbations than the control group during 52-week follow-up (P <0.05). At 24 weeks, the trial group improved in CAT, mMRC, and 6MWT compared to the control (P <0.05), with mMRC and 6MWT improvements lasting at week 52. Lung function showed no significant group differences. Metabolomics found 32 different metabolites between healthy and pre-treatment patients, 17 reversing post-treatment. Bioinformatics showed pathway changes in pre-treatment patients reversed after treatment.

CONCLUSION: TCM pattern-based comprehensive therapy reduces acute exacerbation risk and improves quality of life, respiratory symptoms, and exercise tolerance in stable COPD patients, likely by modulating energy, protein, and amino acid metabolism pathways.

Key words: pulmonary disease, chronic obstructive, metabolomics, Traditional Chinese Medicine pattern, Shenqi Wenfei formula, Shenqi Buzhong formula, Shenqi Tiaoshen formula

DING Huanzhang, WANG Hui, YANG Qinjun, MA Xiao, WU Di, LI Qiao, ZHENG Caixia, LU Jiasheng, WU Chengming, HUANG Pingfu, CHEN Zhixiang, WANG Shihan, FENG Jihong, LIU Jian, SUN Dengdi, ZHU Jie, TONG Jiabing, GAO Yating, LI Zegeng. A multicenter randomized controlled trial and metabolomics exploration of Traditional Chinese Medicine pattern-based therapy for stable chronic obstructive pulmonary disease[J]. Journal of Traditional Chinese Medicine, 2026, 46(3): 652-665.

Figures/Tables 7

References 49.

1.	Petousi N, Pavord ID, Couillard S. The Lancet COPD commission: broader questions remain. Lancet 2023; 401: 1569-70. DOI PMID
2.	GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024; 403: 2100-32. DOI PMID
3.	GBD 2021 Forecasting Collaborators. Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet 2024; 403: 2204-56. DOI PMID
4.	Kreuter M, Cottin V. The threat in chronic lung diseases: acute exacerbations. Eur Respir Rev 2017; 26: 170075. DOI URL
5.	Moll M, Silverman EK. Precision approaches to chronic obstructive pulmonary disease management. Annu Rev Med 2024; 75: 247-62. DOI URL
6.	Dekhuijzen PNR, Hass N, Liu J, Dreher M. Daily impact of COPD in younger and older adults: global online survey results from over 1300 patients. COPD 2020; 17: 419-28.
7.	Gruß I, McCreary GM, Ivlev I, et al. Developing a patient-driven chronic obstructive pulmonary disease (COPD) research agenda in the U.S. J Patient Rep Outcomes 2021; 5: 126. DOI PMID
8.	George J, Kong DCM, Stewart K, Ioannides-Demos LL, Santamaria NM. Use of complementary and alternative medicines by patients with chronic obstructive pulmonary disease. Med J Aust 2004; 181: 248-51. DOI PMID
9.	Li JS, Chen RC, Yu XQ, Liu HG. Guidelines of integrated Chinese and Western Medicine for diagnosis and treatment of chronic obstructive pulmonary disease (2022). J Evid Based Med 2023; 16: 565-80. DOI URL
10.	Li JS, Li SY, Xie Y, et al. The effective evaluation on symptoms and quality of life of chronic obstructive pulmonary disease patients treated by comprehensive therapy based on Traditional Chinese Medicine patterns. Complement Ther Med 2013; 21: 595-602. DOI URL
11.	Wang DY, Dong CW, Li ZG, Zhang ZQ, Tong JB, Li D. Clinical study of winter disease and summer treatment acupoint application combined with Liuwei Buqi granule in the treatment of COPD stable period. Liaoning Zhong Yi Yao Da Xue Xue Bao 2019; 21: 87-90.
12.	Wu D, Wang XL, Gao YT, et al. Shenqi Wenfei Formula alleviates chronic obstructive pulmonary disease in rats with pulmonary Qi deficiency syndrome by regulating NLRP3/GSDMD pyroptosis pathway. Nan Fang Yi Ke Da Xue Xue Bao 2023; 43: 1500-8.
13.	Zhou FC, Yang QJ, Wu D, et al. Shenqi Tiaoshen Formula inhibits COPD mediated bone resorption through OPG/RANKL/NF-κB/MMP-9 pathway. Zhong Yao Yao Li Yu Lin Chuang 2024, 40: 54-60.
14.	Wang H, Yang QJ, Zhou FC, Yang C, Tong JB, Li ZG. To investigate the effect of Shenqi Tiaoshen formula on CSE induced inflammatory response of MH-S cells based on TLR4/NF-kB/NLRP3 pathway. Hainan Yi Xue Yuan Xue Bao 2023; 29: 1295-301.
15.	Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, 2021 report. GOLD serial online, 2020-11-30, cited 2021-05-13; 20-36 screens. Available from URL: http://www.goldcopd.org.
16.	China Association of Chinese Medicine. Guidelines for TCM Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (2019 Version) [T/CACM 1319-2019]. China Association of Chinese Medicine serial online, 2022-07-12, cited 2021-05-13; 14-17 screens. Available from URL: https://hxxtzx.hactcm.edu.cn/info/1148/2669.htm.
17.	China Food and Drug Administration. Good Manufacturing Practice for Medical Products (2015 Revision). Order No. 13. National Medical Products Administration serial online, 2015-07-01, cited 2021-12-05; 1-8 screens. Available from URL: https://www.nmpa.gov.cn/yaopin/ypfgwj/ypfgbmgzh/20150701120001394.html.
18.	Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204. DOI PMID
19.	Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34: 648-54. DOI PMID
20.	Sunjaya A, Poulos L, Reddel H, Jenkins C. Qualitative validation of the modified Medical Research Council (mMRC) dyspnoea scale as a patient-reported measure of breathlessness severity. Respir Med 2022; 203: 106984. DOI URL
21.	Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 2014; 44: 1428-46. DOI PMID
22.	Lenferink A, Brusse-Keizer M, Van der Valk PD, et al. Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2017; 8: CD011682.
23.	Wang MH, Li JS, Li SY, Xie Y. Effects of comprehensive therapy based on Traditional Chinese Medicine patterns on older patients with chronic obstructive pulmonary disease: a subgroup analysis from a four-center, randomized, controlled study. Front Med 2014; 8: 368-75. DOI URL
24.	Chow SC, Shao J, Wang HS, Lokhnygina Y. Sample Size Calculation in Clinical Research. 3rd ed. New York: Chapman and Hall/CRC 2017: 100-10.
25.	Cao GD, Song ZB, Hong YJ, et al. Large-scale targeted metabolomics method for metabolite profiling of human samples. Anal Chim Acta 2020; 1125: 144-51. DOI PMID
26.	Zheng FJ, Zhao XJ, Zeng ZD, et al. Development of a plasma pseudotargeted metabolomics method based on ultra-high-performance liquid chromatography-mass spectrometry. Nat Protoc 2020; 15: 2519-37. DOI PMID
27.	Dransfield MT, Kunisaki KM, Strand MJ, et al. Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017; 195: 324-30. DOI URL
28.	Jacobsen PA, Kragholm KH, Torp-Pedersen C, Janssen DJA, Spruit MA, Weinreich UM. Employment status, readmission and mortality after acute exacerbation of COPD. Int J Chron Obstruct Pulmon Dis 2021; 16: 2257-65. DOI URL
29.	Du YP, Lin J, Wang XX, et al. Early pulmonary rehabilitation in acute exacerbation of chronic obstructive pulmonary disease: a Meta-analysis of randomized controlled trials. COPD 2022; 19: 69-80. DOI URL
30.	Camac ER, Voelker H, Criner GJ. COPD Clinical Research Network and the Canadian Institutes of Health Research. Impact of COPD exacerbations leading to hospitalization on general and disease-specific quality of life. Respir Med 2021; 186: 106526. DOI URL
31.	Zhang YB, Chen F, Sun M, et al. Dongtian Changchun ointment for moderate-to-severe chronic obstructive pulmonary disease: a multicenter, prospective, open-label, randomized controlled trial. J Tradit Chin Med 2025; 45: 1395-404.
32.	Ma JF, Zheng JP, Zhong NS, et al. Effects of Yupingfeng granules on acute exacerbations of COPD: a randomized, placebo-controlled study. Int J Chron Obstruct Pulmon Dis 2018; 13: 3107-14. DOI URL
33.	Chen YB, Gong X, Zhou MJ, et al. Treatment with JianPiYiFei II granules for patients with moderate to very severe chronic obstructive pulmonary disease: a 52-week randomised, double-blinded, placebo-controlled, multicentre trial. Phytomedicine 2022; 100: 154057. DOI URL
34.	Crisan AF, Pescaru CC, Maritescu A, Stoicescu ER, Carunta V, Oancea C. The impact of chronic obstructive pulmonary disease severity on psychological and functional outcomes: a cross-sectional analysis. J Clin Med 2025; 14: 1865. DOI URL
35.	Sundh J, Janson C, Lisspers K, Ställberg B, Montgomery S. The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE) index is predictive of mortality in COPD. Prim Care Respir J 2012; 21: 295-301. DOI URL
36.	Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434-40. DOI PMID
37.	Cen J, Weng L. Comparison of peak expiratory flow (PEF) and COPD assessment test (CAT) to assess COPD exacerbation requiring hospitalization: a prospective observational study. Chron Respir Dis 2022; 19: 14799731221081859.
38.	Wu JJ, Xu HR, Zhang YX, et al. The characteristics of the frequent exacerbator with chronic bronchitis phenotype and non-exacerbator phenotype in patients with chronic obstructive pulmonary disease: a Meta-analysis and system review. BMC Pulm Med 2020; 20: 103. DOI
39.	Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004; 23: 28-33. DOI PMID
40.	Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-54. DOI URL
41.	Liu YB, Hong JR, Jiang N, et al. The role of mitochondrial quality control in chronic obstructive pulmonary disease. Lab Invest 2024; 104: 100307. DOI URL
42.	Pokharel MD, Garcia-Flores A, Marciano D, et al. Mitochondrial network dynamics in pulmonary disease: bridging the gap between inflammation, oxidative stress, and bioenergetics. Redox Biol 2024; 70: 103049. DOI URL
43.	Martínez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun 2020; 11: 102. DOI PMID
44.	Pålsson-McDermott EM, O’Neill LAJ. Targeting immunometabolism as an anti-inflammatory strategy. Cell Res 2020; 30: 300-14. DOI PMID
45.	Finamore P, Lattanzi G, Pedone C, et al. Energy expenditure and intake in COPD: the extent of unnoticed unbalance by predicting REE. Respir Med 2022; 201: 106951. DOI URL
46.	Naz S, Kolmert J, Yang M, et al. Metabolomics analysis identifies sex-associated metabotypes of oxidative stress and the autotaxin-lysoPA axis in COPD. Eur Respir J 2017; 49: 1602322. DOI URL
47.	Xue MS, Zeng YF, Lin RP, et al. Metabolomic profiling of anaerobic and aerobic energy metabolic pathways in chronic obstructive pulmonary disease. Exp Biol Med (Maywood) 2021; 246: 1586-96. DOI URL
48.	Peng L, You H, Xu MY, et al. A novel metabolic score for predicting the acute exacerbation in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2023; 18: 785-95. DOI URL
49.	Pinto-Plata V, Casanova C, Divo M, et al. Plasma metabolomics and clinical predictors of survival differences in COPD patients. Respir Res 2019; 20: 219. DOI

Characteristic	Intent-to-treat analysis set			Per-protocol analysis set
Characteristic	Trial group (n = 180)	Control group (n = 90)	P value	Trial group (n = 174)	Control group (n = 82)	P value
Age (years, $\overline{x}$ ± s)	68.0±6.1	67.1±6.8	0.361	68.0±6.1	66.7±6.8	0.185
Male [n (%)]	143 (79.4)	78 (86.7)	0.147	138 (79.3)	72 (87.8)	0.099
BMI ($\overline{x}$ ± s)	23.0±3.9	23.7±3.4	0.132	22.9±3.9	23.6±3.5	0.163
Smoking history [n (%)]			0.839			0.999
Never smoking	51 (28.3)	26 (28.9)		40 (23.0)	19 (23.2)
Current smoking	41 (22.8)	23 (25.6)		85 (48.9)	40 (48.8)
Former smoking	88 (48.9)	41 (45.6)		49 (28.2)	23 (28.0)
Gold stage [n (%)]			0.209			0.178
GOLD 1	15 (8.3)	3 (3.3)		15 (8.6)	3 (3.7)
GOLD 2	63 (35.0)	36 (40.0)		60 (34.5)	33 (40.2)
GOLD 3	75 (41.7)	32 (35.6)		73 (42.0)	28 (34.1)
GOLD 4	27 (15.0)	19 (21.1)		26 (14.9)	18 (22.0)
Medication use [n (%)]			0.907			0.911
None	68 (37.8)	34 (37.8)		64 (36.8)	34 (41.5)
ICS/LABA	42 (23.3)	24 (26.7)		42 (24.1)	19 (23.2)
LAMA	42 (23.3)	17 (18.9)		40 (23.0)	15 (18.3)
LABA+LAMA	13 (7.2)	6 (6.7)		13 (7.5)	6 (7.3)
ICS/LABA+LAMA	15 (8.3)	9 (10.0)		15 (8.6)	8 (9.8)
Exacerbations, previous 52 weeks [median (IQR)]	1 (0.25, 2)	1 (0, 2)	0.310	1 (0, 2)	1 (0, 2)	0.323
Exacerbations, previous 52 weeks [n (%)]			0.647			0.624
0 acute exacerbation	45 (25.0)	28 (31.1)		45 (25.9)	27 (32.9)
1 acute exacerbation	67 (37.2)	32 (35.6)		64 (36.8)	28 (34.1)
2 acute exacerbation	44 (24.4)	19 (21.1)		42 (24.1)	16 (19.5)
3 acute exacerbation	15 (8.3)	9 (10.0)		15 (8.6)	9 (11.0)
>3 acute exacerbation	9 (5.0)	2 (2.2)		8 (4.6)	2 (2.4)
6MWT in metres ($\overline{x}$ ± s)	397.0±95.2	399.1±100.1	0.866	398.2±92.2	399.8±101.5	0.900
CAT scores ($\overline{x}$ ± s)	20.0±7.0	19.9±7.1	0.978	19.8±7.1	19.9±7.2	0.945
mMRC scores [median (IQR)]	2 (1, 3)	2 (1, 3)	0.520	2 (1, 3)	2 (1, 3)	0.581
Lung function
FEV₁ (L, $\overline{x}$ ± s)	1.2±0.5	1.3±0.5	0.583	1.2±0.5	1.3±0.5	0.515
FEV₁%pred ($\overline{x}$ ± s)	48.5±19.2	46.0±18.3	0.353	48.7±19.4	46.1±18.4	0.359
FVC (L, $\overline{x}$ ± s)	2.2±0.8	2.3±0.7	0.355	2.3±0.8	2.3±0.7	0.360
FEV₁/FVC% (%, $\overline{x}$ ± s)	53.6±9.5	53.2±9.8	0.746	53.5±9.5	53.4±10.1	0.941

Characteristic	Intent-to-treat analysis set			Per-protocol analysis set
Characteristic	Trial group (n = 180)	Control group (n = 90)	P value	Trial group (n = 174)	Control group (n = 82)	P value
Age (years, $\overline{x}$ ± s)	68.0±6.1	67.1±6.8	0.361	68.0±6.1	66.7±6.8	0.185
Male [n (%)]	143 (79.4)	78 (86.7)	0.147	138 (79.3)	72 (87.8)	0.099
BMI ($\overline{x}$ ± s)	23.0±3.9	23.7±3.4	0.132	22.9±3.9	23.6±3.5	0.163
Smoking history [n (%)]			0.839			0.999
Never smoking	51 (28.3)	26 (28.9)		40 (23.0)	19 (23.2)
Current smoking	41 (22.8)	23 (25.6)		85 (48.9)	40 (48.8)
Former smoking	88 (48.9)	41 (45.6)		49 (28.2)	23 (28.0)
Gold stage [n (%)]			0.209			0.178
GOLD 1	15 (8.3)	3 (3.3)		15 (8.6)	3 (3.7)
GOLD 2	63 (35.0)	36 (40.0)		60 (34.5)	33 (40.2)
GOLD 3	75 (41.7)	32 (35.6)		73 (42.0)	28 (34.1)
GOLD 4	27 (15.0)	19 (21.1)		26 (14.9)	18 (22.0)
Medication use [n (%)]			0.907			0.911
None	68 (37.8)	34 (37.8)		64 (36.8)	34 (41.5)
ICS/LABA	42 (23.3)	24 (26.7)		42 (24.1)	19 (23.2)
LAMA	42 (23.3)	17 (18.9)		40 (23.0)	15 (18.3)
LABA+LAMA	13 (7.2)	6 (6.7)		13 (7.5)	6 (7.3)
ICS/LABA+LAMA	15 (8.3)	9 (10.0)		15 (8.6)	8 (9.8)
Exacerbations, previous 52 weeks [median (IQR)]	1 (0.25, 2)	1 (0, 2)	0.310	1 (0, 2)	1 (0, 2)	0.323
Exacerbations, previous 52 weeks [n (%)]			0.647			0.624
0 acute exacerbation	45 (25.0)	28 (31.1)		45 (25.9)	27 (32.9)
1 acute exacerbation	67 (37.2)	32 (35.6)		64 (36.8)	28 (34.1)
2 acute exacerbation	44 (24.4)	19 (21.1)		42 (24.1)	16 (19.5)
3 acute exacerbation	15 (8.3)	9 (10.0)		15 (8.6)	9 (11.0)
>3 acute exacerbation	9 (5.0)	2 (2.2)		8 (4.6)	2 (2.4)
6MWT in metres ($\overline{x}$ ± s)	397.0±95.2	399.1±100.1	0.866	398.2±92.2	399.8±101.5	0.900
CAT scores ($\overline{x}$ ± s)	20.0±7.0	19.9±7.1	0.978	19.8±7.1	19.9±7.2	0.945
mMRC scores [median (IQR)]	2 (1, 3)	2 (1, 3)	0.520	2 (1, 3)	2 (1, 3)	0.581
Lung function
FEV₁ (L, $\overline{x}$ ± s)	1.2±0.5	1.3±0.5	0.583	1.2±0.5	1.3±0.5	0.515
FEV₁%pred ($\overline{x}$ ± s)	48.5±19.2	46.0±18.3	0.353	48.7±19.4	46.1±18.4	0.359
FVC (L, $\overline{x}$ ± s)	2.2±0.8	2.3±0.7	0.355	2.3±0.8	2.3±0.7	0.360
FEV₁/FVC% (%, $\overline{x}$ ± s)	53.6±9.5	53.2±9.8	0.746	53.5±9.5	53.4±10.1	0.941

Item	Intent-to-treat analysis set				Per-protocol analysis set
Item	Trial group (n = 180)	Control group (n = 90)	χ²/Z value	P value	Trial group (n = 174)	Control group (n = 82)	χ²/Z value	P value
Number of exacerbation events [n (%)]			11.518	0.021			13.898	0.008
0 acute exacerbation	97 (53.9)	37 (41.1)			97 (55.7)	36 (43.9)
1 acute exacerbation	37 (20.6)	26 (28.9)			34 (19.5)	22 (26.8)
2 acute exacerbation	33 (18.3)	11 (12.2)			31 (17.8)	8 (9.8)
3 acute exacerbation	9 (5)	10 (11.1)			9 (5.2)	10 (12.2)
>3 acute exacerbation	4 (2.2)	6 (6.7)			3 (1.7)	6 (7.3)
Number of exacerbation events [median (IQR)]	0 (0, 2)	1 (0, 2)	－2.036	0.042	0 (0, 1.25)	1 (0, 2)	－1.961	0.049

Item	Intent-to-treat analysis set				Per-protocol analysis set
Item	Trial group (n = 180)	Control group (n = 90)	χ²/Z value	P value	Trial group (n = 174)	Control group (n = 82)	χ²/Z value	P value
Number of exacerbation events [n (%)]			11.518	0.021			13.898	0.008
0 acute exacerbation	97 (53.9)	37 (41.1)			97 (55.7)	36 (43.9)
1 acute exacerbation	37 (20.6)	26 (28.9)			34 (19.5)	22 (26.8)
2 acute exacerbation	33 (18.3)	11 (12.2)			31 (17.8)	8 (9.8)
3 acute exacerbation	9 (5)	10 (11.1)			9 (5.2)	10 (12.2)
>3 acute exacerbation	4 (2.2)	6 (6.7)			3 (1.7)	6 (7.3)
Number of exacerbation events [median (IQR)]	0 (0, 2)	1 (0, 2)	－2.036	0.042	0 (0, 1.25)	1 (0, 2)	－1.961	0.049

Item		Intent-to-treat analysis set			Per-protocol analysis set
Item		0 Week	24 Week	52 Week	0 Week	24 Week	52 Week
CAT ($\overline{x}$± s)	Trial group	20±7	16±6	17±7	20±7	16±6	17±7
	Control group	20±7	18±7	18±7	20±7	18±7	18±7
	Estimate (95% CI)	0.000 (－2.000, 2.000)	－1.799 (－3.120, －0.479)	－1.366 (－2.748, 0.016)	0.000 (－2.000, 2.000)	－1.622 (－3.023, －0.221)	－1.200 (－2.663, 0.263)
	χ ²/Z value	－0.027	7.130	3.753	－0.069	5.147	2.586
	P value	0.978	0.008	0.053	0.945	0.023	0.108
mMRC [median (IQR)]	Trial group	2 (1, 3)	2 (1, 2)	2 (1, 2)	2 (1, 3)	2 (1, 2)	2 (1, 2)
	Control group	2 (1, 3)	2 (1, 3)	2 (1, 3)	2 (1, 3)	2 (1, 3)	2 (1, 3)
	Estimate (95% CI)	0.000 (0.000, 0.000)	－0.581 (－1.059, －0.102)	－0.712 (－1.258, －0.166)	0.000 (0.000, 0.000)	－0.584 (－1.097, －0.070)	－0.745 (－1.319, －0.171)
	χ ²/Z value	－0.644	5.657	6.541	－0.551	4.967	6.478
	P value	0.520	0.017	0.011	0.581	0.026	0.011
6MWT ($\overline{x}$ ± s)	Trial group	397±95	417±90	407±95	398±92	419±88	408±93
	Control group	399±100	392±100	383±105	400±102	392±102	383±107
	Estimate (95% CI)	－2.111 (－26.733, 22.511)	27.105 (16.924, 37.285)	25.598 (14.891, 36.305)	－1.599 (－26.724, 23.525)	27.483 (16.630, 38.335)	26.323 (14.946, 37.701)
	χ ²/Z value	－0.169	27.230	21.958	－0.125	24.636	20.563
	P value	0.866	0.000	0.000	0.900	0.000	0.000

Home

Online First

Author Center

Reviewer Center

Issues

Announcement

About Us

A multicenter randomized controlled trial and metabolomics exploration of Traditional Chinese Medicine pattern-based therapy for stable chronic obstructive pulmonary disease

RichHTML

PDF

Supplement

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 7

References 49.

Related Articles 15

Recommended Articles

Metrics

Comments

Type of adverse event	Trial group	Control group
Nausea	1	0
Bloating	7	2
Diarrhea	3	1
Urticaria	1	0
Joint pain	3	2
Palpitation	0	1
Acute myocardial infarction	0	1
Deep venous thrombosis	1	0
Periodontitis	2	1
Cervical spondylopathy	1	1
Urinary tract infection	2	2
Gallstone	0	1
Lung cancer	1	0
Solitary pulmonary nodule	2	2
Mouth ulcers	0	1
Constipation	1	2
Hypertension	2	1
Fracture	0	1

[1]	CHEN Ying, QIAO Jiajun, LU Yuyuan, XUE Chongxiang, XIA Zhongyuan. Mechanism of Buzhong Yiqi decoction (补中益气汤) for Hashimoto's thyroiditis: insights from gut microbiota and metabolomics [J]. Journal of Traditional Chinese Medicine, 2026, 46(3): 571-583.
[2]	SHI Bing, LI Yang, JIANG Zhuocheng, QIN Guozheng, ZHAO Fan. Mechanic evaluation of Jisheng Shenqi Wan (济生肾气丸) on calcium oxalate kidney stones: an integrated network pharmacology and metabolomics [J]. Journal of Traditional Chinese Medicine, 2026, 46(2): 371-381.
[3]	JIA Ao, LIU Shuang, GAO Tingting, ZHANG Haoran, GAO Wenyuan, WU Xiongzhi. Mechanisms of Gualou Beimu Yin (瓜蒌贝母饮) in suppressing the development and metastasis of triple-negative breast cancer: an integrated study based on network pharmacology, transcriptomics, and metabolomics [J]. Journal of Traditional Chinese Medicine, 2026, 46(1): 149-159.
[4]	ZHANG Yuan, CHENG Shizan, HUA Yue, SHI Ji, SU Guoming, ZHANG Chao, LIAN Jing, LIU Pengpeng, JIA Tianzhu. Mechanisms of Suanzaoren (Ziziphi Spinosae Semen) and its processed products in treating insomnia: an integrated study based on network pharmacology and metabolomics [J]. Journal of Traditional Chinese Medicine, 2025, 45(6): 1307-1316.
[5]	CHENG Ziqi, DONG Xin, Temuribagen , XU Caimeng, HU Shaonan, CHEN Qianwen, WANG Yuewu, WANG Haibo, HE Xiaoyu, XUE Dan, XUE Peifeng. Exploration of the mechanism of the Mongolian medicine Tonglaga-5 (通拉嘎-5) for the treatment of n-methyl-n′-nitro-n-nitrosoguanidine-induced chronic atrophic gastritis based on network pharmacology and metabolomics [J]. Journal of Traditional Chinese Medicine, 2025, 45(6): 1366-1375.
[6]	WANG Yue, LIU Xingxing, GUO Yi, GUO Yongming, YUAN Gongming, ZHANG Yu, ZHENG Zhiyu, XU Yuan, LI Yuan. Characterization of acupuncture on central amino acid metabolism based on targeted neurotransmitter analysis in mice with inflammatory pain [J]. Journal of Traditional Chinese Medicine, 2025, 45(5): 1019-1027.
[7]	PAN Tingyu, YAO Jing, GE Yue, YANG Shuang, SUN Zikai, WEI Yu, WU Jieyu, XU Yong, ZHOU Xianmei, HE Hailang. Liquid chromatography-mass spectrometry-based metabolomics study of the protective mechanism of Shenji Guben decoction (参吉固本方) on chronic obstructive pulmonary disease [J]. Journal of Traditional Chinese Medicine, 2025, 45(5): 1009-1018.
[8]	WANG Raoqiong, HAO Linyao, LU Ye, WANG Lingxue, LI Jianrong, PENG Yan, TANG Hongmei, LI Shuangyang, BAI Xue. Mechanism analysis of Tongqiao Yizhi decoction (通窍益智颗粒) in treating vascular dementia rats by brain tissue untargeted metabonomics and fecal 16S rRNA gene sequencing [J]. Journal of Traditional Chinese Medicine, 2025, 45(4): 759-769.
[9]	GAO Jiaming, ZHANG Yehao, Chen Yuanyuan, JIN Long, ZHAO Jianfeng, GUO Hao, FU Jianhua. Qingfei Zhisou oral liquid (清肺止嗽口服液) alleviates fever-induced inflammation by regulating arachidonic acid and lysophospholipids metabolism and inhibiting hypothalamus transient receptor potential ion channels expression [J]. Journal of Traditional Chinese Medicine, 2024, 44(5): 954-962.
[10]	YANG Qinjun, YIN Dandan, WANG Hui, GAO Yating, WANG Xinheng, WU Di, TONG Jiabing, WANG Chuanbo, LI Zegeng. Uncovering the action mechanism of Shenqi Tiaoshen formula (参芪调肾方) in the treatment of chronic obstructive pulmonary disease through network pharmacology, molecular docking, and experimental verification [J]. Journal of Traditional Chinese Medicine, 2024, 44(4): 770-783.
[11]	YAN Jing, FENG Huimin, QIU Fang, WANG Haijun, YIN Luyun, JIN Xiaofei, ZHAO Jiyu, WANG Hongyang, YAN Xiaoqin. Effect on serum metabolomics of rats with premature ovarian insufficiency by Zhibian (BL54) through Shuidao (ST28) acupuncture [J]. Journal of Traditional Chinese Medicine, 2024, 44(4): 722-733.
[12]	SONG Zhenguang, YANG Bin, WANG Fei, YAN Dongmei, ZHOU Xiaoqing, HUANG Liping, GAO Xuemei, LI Bin, HUANG Luqi. Study on the four Qi of Pfaffia glomerata based on the metabolomics technology and comparison of Dangshen (Radix Codonopsis) in the equivalent substitution prescription [J]. Journal of Traditional Chinese Medicine, 2024, 44(4): 713-721.
[13]	WANG Xiang, HUANG Jianping, WANG Yupeng, WANG Qilong, JING Yajiang, ZHANG Gang, PENG Liang, GAO Jing, WANG Hongyan, YAN Yonggang. Differential metabolite analysis of the pharmacodynamic differences between different ratios of Dahuang (Radix Et Rhizoma Rhei Palmati)-Taoren (Semen Persicae) herb pair [J]. Journal of Traditional Chinese Medicine, 2024, 44(3): 515-523.
[14]	JING Wenguang, LIN Xiaoyu, LI Chu, ZHAO Xiaoliang, CHENG Xianlong, WANG Penglong, WEI Feng, MA Shuangcheng. Anti-inflammatory mechanism of the non-volatile ingredients originated from Guanghuoxiang (Pogostemonis Herba) based on high performance liquid chromatography-heated electron spray ionization-high resolution mass spectroscope and cell metabolomics [J]. Journal of Traditional Chinese Medicine, 2024, 44(2): 260-267.
[15]	WANG Miao, ZHU Yan, ZHAO Hui, ZHAO Hongfang. Moxibustion enables protective effects on rheumatoid arthritis-induced myocardial injury via transforming growth factor beta1 signaling and metabolic reprogramming [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1190-1199.

Item		Intent-to-treat analysis set			Per-protocol analysis set
Item		0 Week	24 Week	52 Week	0 Week	24 Week	52 Week
FEV₁ (L, $\overline{x}$ ± s)	Trial group	1.2±0.5	1.2±0.6	1.2±0.5	1.2±0.5	1.2±0.6	1.2±0.5
	Control group	1.3±0.5	1.3±0.5	1.2±0.5	1.3±0.5	1.3±0.5	1.2±0.5
	Estimate (95% CI)	－0.031 (－0.167, 0.090)	0.006 (－0.056, 0.067)	0.008 (－0.054, 0.070)	－0.040 (－0.184, 0.092)	－0.006 (－0.067, 0.055)	－0.000 (－0.063, 0.063)
	χ ²/Z value	－0.549	0.032	0.067	－0.650	0.037	0.000
	P value	0.583	0.858	0.795	0.515	0.848	0.995
FEV₁%pred (%,$\overline{x}$ ± s)	Trial group	48.5±19.3	48.5±20.3	47.3±19.7	48.7±19.4	48.8±20.4	47.6±19.8
	Control group	46.0±18.3	46.0±16.4	44.438±17.5	46.1±18.4	46.6±16.6	44.8±17.8
	Estimate (95% CI)	2.021 (－2.501, 7.010)	0.473 (－2.040, 2.986)	0.932 (－1.400, 3.264)	2.681 (－2.810, 7.730)	0.152 (－2.443, 2.747)	0.727 (－1.666, 3.120)
	χ ²/Z value	－0.928	0.136	0.613	－0.916	0.013	0.355
	P value	0.353	0.712	0.434	0.359	0.909	0.551
FVC (L, $\overline{x}$ ± s)	Trial group	2.2±0.8	2.2±0.8	2.2±0.7	2.3±0.8	2.3±0.8	2.3±0.7
	Control group	2.3±0.7	2.3±0.7	2.3±0.7	2.3±0.7	2.4±0.7	2.3±0.7
	Estimate (95% CI)	－0.090 (－0.291, 0.105)	－0.033 (－0.126, 0.059)	－0.004 (－0.085, 0.077)	－0.091 (－0.301, 0.118)	－0.047 (－0.144, 0.049)	－0.016 (－0.099, 0.068)
	χ ²/Z value	－0.924	0.5	0.01	－0.914	0.939	0.137
	P value	0.355	0.479	0.920	0.360	0.332	0.712
FEV₁/FVC (%,$\overline{x}$ ± s)	Trial group	53.6±9.5	54.2±10.0	51.8±11.1	53.5±9.5	54.0±10.0	51.5±11.2
	Control group	53.2±9.8	53.2±9.9	51.4±10.6	53.4±10.1	53.4±10.0	51.5±10.8
	Estimate (95% CI)	0.402 (－2.036, 2.839)	0.867 (－0.735, 2.469)	0.205 (－1.413, 1.823)	0.096 (－2.457, 2.649)	0.775 (－0.913, 2.463)	0.201 (－1.501, 1.904)
	χ ²/Z value	0.324	1.124	0.062	0.074	0.809	0.054
	P value	0.746	0.289	0.804	0.941	0.368	0.817

Item		Intent-to-treat analysis set			Per-protocol analysis set
Item		0 Week	24 Week	52 Week	0 Week	24 Week	52 Week
FEV₁ (L, $\overline{x}$ ± s)	Trial group	1.2±0.5	1.2±0.6	1.2±0.5	1.2±0.5	1.2±0.6	1.2±0.5
	Control group	1.3±0.5	1.3±0.5	1.2±0.5	1.3±0.5	1.3±0.5	1.2±0.5
	Estimate (95% CI)	－0.031 (－0.167, 0.090)	0.006 (－0.056, 0.067)	0.008 (－0.054, 0.070)	－0.040 (－0.184, 0.092)	－0.006 (－0.067, 0.055)	－0.000 (－0.063, 0.063)
	χ ²/Z value	－0.549	0.032	0.067	－0.650	0.037	0.000
	P value	0.583	0.858	0.795	0.515	0.848	0.995
FEV₁%pred (%,$\overline{x}$ ± s)	Trial group	48.5±19.3	48.5±20.3	47.3±19.7	48.7±19.4	48.8±20.4	47.6±19.8
	Control group	46.0±18.3	46.0±16.4	44.438±17.5	46.1±18.4	46.6±16.6	44.8±17.8
	Estimate (95% CI)	2.021 (－2.501, 7.010)	0.473 (－2.040, 2.986)	0.932 (－1.400, 3.264)	2.681 (－2.810, 7.730)	0.152 (－2.443, 2.747)	0.727 (－1.666, 3.120)
	χ ²/Z value	－0.928	0.136	0.613	－0.916	0.013	0.355
	P value	0.353	0.712	0.434	0.359	0.909	0.551
FVC (L, $\overline{x}$ ± s)	Trial group	2.2±0.8	2.2±0.8	2.2±0.7	2.3±0.8	2.3±0.8	2.3±0.7
	Control group	2.3±0.7	2.3±0.7	2.3±0.7	2.3±0.7	2.4±0.7	2.3±0.7
	Estimate (95% CI)	－0.090 (－0.291, 0.105)	－0.033 (－0.126, 0.059)	－0.004 (－0.085, 0.077)	－0.091 (－0.301, 0.118)	－0.047 (－0.144, 0.049)	－0.016 (－0.099, 0.068)
	χ ²/Z value	－0.924	0.5	0.01	－0.914	0.939	0.137
	P value	0.355	0.479	0.920	0.360	0.332	0.712
FEV₁/FVC (%,$\overline{x}$ ± s)	Trial group	53.6±9.5	54.2±10.0	51.8±11.1	53.5±9.5	54.0±10.0	51.5±11.2
	Control group	53.2±9.8	53.2±9.9	51.4±10.6	53.4±10.1	53.4±10.0	51.5±10.8
	Estimate (95% CI)	0.402 (－2.036, 2.839)	0.867 (－0.735, 2.469)	0.205 (－1.413, 1.823)	0.096 (－2.457, 2.649)	0.775 (－0.913, 2.463)	0.201 (－1.501, 1.904)
	χ ²/Z value	0.324	1.124	0.062	0.074	0.809	0.054
	P value	0.746	0.289	0.804	0.941	0.368	0.817